VC: Microbia leads with a massive $75M round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Microbia
Cambridge, MA

$75M
Fifth

Sigma Capital Management, Jennison Associates and Maverick Capital

An anti-constipation pill is now in a mid-stage trial and a cholesterol-blocking pill is in an early-stage study.

Neuromed Pharmaceuticals
Conshohocken, PA

$25M
Fourth

MPM Capital

Neuromed will use the funds to advance its lead program for developing calcium channel blockers for chronic pain.

Nereus Pharmaceuticals
San Diego

$18.3M
Second tranche of fourth round

HBM BioVentures and HBM BioCapital LP

The tranche was triggered by the company's success at hitting milestones in its drug development work.

ARCA Discovery
Boulder, CO

$15M
First

Atlas Venture

This round of financing allows ARCA to complete the filing of an NDA for bucindolol, a genetically-targeted cardiovascular drug.

Ikonisys
New Haven, CT

$10M
Fourth

Trevi Health Ventures

Ikonisys expects to advance its prenatal diagnostics program to FDA submission and further develop its oncology program.

Cytomics Systems
France

€10M
Second

Edmond de Rothschild Investment Partners and Truffle Venture

This round will enable the company to accelerate the development of its most advanced antifungal compounds.